Levetiracetam Relonchem (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A. This binding modulates neurotransmitter release, stabilizes neuronal firing, and diminishes excessive synaptic excitation, thereby preventing the rapid, uncontrolled electrical discharges that cause seizures.

The appropriate dose of Levetiracetam Relonchem is individualized by the prescribing healthcare professional. Factors such as the patient’s age, renal function, seizure type, and response to therapy guide the prescriber’s decision on the exact dosage regimen.

Safety data for levetiracetam in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug is excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Levetiracetam Relonchem. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levetiracetam is distinguished by its unique SV2A binding mechanism, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproic acid. It generally has a favorable drug‑interaction profile, fewer enzyme‑inducing effects, and is often chosen for patients who need a well‑tolerated option with minimal hepatic metabolism.

Levetiracetam Relonchem should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Levetiracetam Relonchem is administered orally, typically as a tablet taken with or without food. The exact timing and frequency are determined by the prescriber, who may adjust the schedule based on the patient’s seizure pattern and renal function.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, emergence of suicidal thoughts or major depression, and hematologic abnormalities like leukopenia or thrombocytopenia. Patients should seek immediate medical attention if they notice rash, mood changes, or signs of infection.

Levetiracetam Relonchem is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment who may require dose adjustment, and it should be avoided in pregnant women unless the therapeutic benefit justifies potential risks.